Tarsus Patent-Cliff Exposure & CMS Drug Spending Portfolio

Tarsus (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $123.4M 2024 CMS Part D & Medicaid spend, and $1,850 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2038-01-01
2024 CMS Total Public Spend$123.4M
2024 Medicare Part D Spend$114.3M
2024 Medicaid Spend$9.2M
California HCAI SB 17 FilingsSpecialty launch notice ($1,850 intro WAC)